Home / Clinical Decision Support & Reference / OphtAI

OphtAI

by OphtAI · Based in France → — Artificial intelligence for ophthalmology

Ophthalmology

Website Demo Contact API Docs

Claim this tool

Is this the maker? Claim the company →

Leave this field empty

Correct company / maker

Company website (optional)

Anything else? (optional)

Subscription-based

Documentation Provided

Overview

OphtAI is an artificial intelligence platform developed by the French group Evolucare Technologies, designed to assist healthcare professionals in the early detection and screening of major retinal pathologies. The platform analyzes standard field color retinograph images in real-time to identify risks associated with Diabetic Retinopathy, Glaucoma, and Age-related Macular Degeneration (AMD).

The system offers a streamlined workflow: capture retinal images, send them to OphtAI for analysis via web, desktop application, or API, and receive detailed PDF reports within seconds. This rapid analysis includes photo quality assessment, severity rating for Diabetic Retinopathy, localization of detected lesions, and a confidence score for the findings.

OphtAI is built on a collaborative foundation, stemming from a project with AP-HP hospitals and the Latim research laboratory, ensuring a strong clinical and research basis. It aims to enhance screening capabilities, particularly in contexts facing a rise in chronic eye conditions and a shortage of ophthalmologists, by providing an efficient and reliable AI-powered diagnostic aid.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

Retinal photo analysis
Detection of Diabetic Retinopathy, Glaucoma, AMD
Real-time analysis
Detailed PDF reports
Photo quality assessment
Severity rating (Diabetic Retinopathy)
Location of detected lesions
Confidence score
Customizable summary report
Compatible with standard field color retinographs

Use Cases

Automated screening for retinal diseases
Early detection of diabetic retinopathy
Glaucoma risk assessment
AMD detection
Large-scale population screening programs
Support for ophthalmologists and general practitioners

What Physicians Need to Know

Evidence Base

OphtAI's algorithms are trained using large datasets, including over 800,000 images from patients screened in Paris hospitals, France, and validated on over 300,000 retinal images from over 23,000 military veterans. The solution is a result of clinical and scientific research, developed in partnership with AP-HP and its Ophdiat network, and the LATIM research laboratory (UBO/INSERM). OphtAI also provides guidance on management based on recommendations from professional societies.

Clinical Validation Studies

OphtAI has undergone clinical validation, including the OphtAI-Eval study, a prospective, multicenter, post-marketing clinical follow-up study to validate its diagnostic performance for automated screening of diabetic retinopathy (DR), diabetic macular edema (DME), glaucoma, Age-related Maculopathy (ARM), and Age-related Macular Degeneration (AMD). A large validation study published in the ADA Diabetes Care journal showed OphtAI DR to be the only participant providing better results than an ophthalmologist for DR assessment, with statistically better sensitivity than human screeners. In this multicenter study, OphtAI DR analyzed over 300,000 retinal images from more than 23,000 military veterans. OphtAI is a CE-marked medical device and is certified by Health Canada and under the UKCA register.

Alert Fatigue Management

OphtAI contributes to managing alert fatigue by automating the initial review of images and sorting cases by urgency, which helps prioritize patients and reduces repetitive tasks for medical staff. This allows specialists to focus on higher-value activities and complex cases.

Differential Diagnosis Support

OphtAI provides differential diagnosis support by detecting and grading the severity of diabetic retinopathy, diabetic macular edema, glaucoma, ARM, and AMD. It offers explicable results through lesion mapping (heatmaps) and confidence indexes, allowing users to understand the AI's decision-making process.

Guideline Update Frequency

While a specific update frequency for guidelines within OphtAI is not explicitly stated, the company emphasizes continuous research and development to expand its artificial intelligence to other imaging modalities and add new disease detections. They are working on releasing a version with 12 new detectors and predictive models to anticipate pathology evolution. Clinical practice guidelines, in general, are typically reviewed and revised every 2-5 years or when new evidence warrants.

Clinical Workflow Integration

OphtAI is designed for seamless integration into clinical workflows. It can be accessed via a web browser (OphtAI WEB), a desktop application (OphtAI APP) for automatic analysis of photos in a PC directory, or through an API for integration into partners' software offerings. It integrates with vendor-neutral data management platforms like Topcon's Harmony Referral System, allowing access regardless of the fundus camera used. The service can launch automatically, streamlining the process and saving significant time for medical staff. It also facilitates administrative management and care coordination by automating file classification, generating standardized reports, and feeding directly into patient medical records.

Decision Audit Trail

OphtAI generates customizable PDF reports that can include details by disease, confidence levels, and lesion mapping. These reports are certified as Medical Devices and can be anonymized on demand. The system also offers accessible patient history through a centralized electronic patient record when integrated with platforms like Evolucare's OphCare. The software design complies with security, traceability, and data protection requirements, processing data in accordance with GDPR. Patient images and data are deleted after processing for security and anonymization purposes.

Physician Tip

OphtAI acts as an expert 'second reader,' capable of analyzing thousands of images without fatigue or cognitive bias, helping to identify subtle abnormalities that might be missed by the human eye. The system provides explicable results with lesion mapping and confidence scores, aiding in understanding the AI's decision. It helps prioritize patients based on urgency, allowing you to focus your expertise on complex or urgent cases and optimize your time. The automated initial review and sorting of images can significantly reduce repetitive tasks, improving overall efficiency in your practice. Remember that AI is a complementary tool that enhances your capabilities, not a replacement for clinical judgment.

OphtAI offers flexible integration options, including a web interface, a desktop application, and an API for seamless integration into existing software and systems. It is compatible with any standard field color retinograph for image capture. Notably, OphtAI partners with Topcon Healthcare Solutions to integrate into their Harmony Referral System, a vendor-neutral data management platform, allowing access to OphtAI's AI services regardless of the color fundus device being used. This facilitates streamlined clinical workflows and provides a single-screen review of all data. The solution is also developed by Evolucare Technologies, a leading healthcare software publisher, suggesting potential for integration with their other offerings like the OphCare platform for centralized electronic patient records.

At a glance

Pricing Subscription-based

Deployment Cloud Hosted, On Premise, Web Based, Mobile App, API

Visit site

Details

Category	Clinical Decision Support & Reference, Ophthalmology AI, Radiology & Imaging AI
Pricing	Subscription-based
Free Trial	Unknown
Deployment	Cloud-hosted, On-premise, Web-based, Mobile App, API
Mobile App	1
API Available	Unknown
Data Export	Unknown
Compliance
BAA Available	Unknown
HIPAA Compliant	Unknown
FDA Status	Unknown
GDPR	Yes AI-estimated
Integrations
EHR	Not specified
Specialties	Ophthalmology

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate OphtAI

Clinical Value

Ease of Use

Integration

Support & Docs

Value for Money

Your Name *

Email *

Your Role

Specialty

Your Review * (min 50 characters)

Press & Coverage

OphtAI News

OphtAI at SANTEXPO 2026: AI for visual screening

OphtAI will be exhibiting at the SANTEXPO 2026 trade fair to present its artificial intelligence solution for screening retinal conditions, addressing public health challenges. The solution detects diabetic retinopathy, glaucoma, and AMD, and offers features like image quality assessment and detailed PDF reports.

2026-04

OphtAI News

OphtAI : AI for ophthalmologists

This article highlights how AI, particularly OphtAI, is transforming ophthalmology by improving early detection of chronic eye conditions and optimizing medical resources. OphtAI offers scientifically validated technology with performance comparable to human experts for diabetic retinopathy, glaucoma, and AMD.

2026-03

OphtAI News

Evolucare OphtAI CE certified according to the MDR

OphtAI, a Class IIa medical device, has obtained MDR certification, signifying its compliance with European regulatory requirements for safety, performance, and traceability in medical devices. This certification is a significant milestone for the company and the ophthalmic e-health sector.

2025-12

OphtAI

AI in teleophthalmology: towards optimised eye screening

This article discusses how AI, such as OphtAI, is revolutionizing teleophthalmology by automating image analysis, securing diagnoses, and increasing data processing volume. It also highlights the ability of OphtAI to detect early abnormalities and facilitate administrative management and care coordination.

2025-10

Klinische Monatsblätter für Augenheilkunde (PubMed)

Automated Diabetic Retinopathy Screening in Out-patient Diabetes Care – Comparison of Two Artificial Intelligence Algorithms: RetCAD and OphtAI

This study compares the performance of RetCAD and OphtAI AI-based algorithms for diabetic retinopathy screening in an outpatient diabetes clinic. It found that while both are suitable for use, OphtAI had a lower sensitivity for detecting moderate diabetic retinopathy compared to RetCAD.

2025-05

Ophthalmology Breaking News (OBN)

AI in Eye Care: Six Tools Influencing Clinical Practice

This article discusses the accelerating adoption of AI in Canadian eye care, with OphtAI supporting retinal screening through automated analysis of color fundus photography. OphtAI screens for diabetic retinopathy, glaucoma, and AMD, generating real-time reports with lesion mapping and severity grading.

2026-00

ArcticToday (Press Release)

Topcon Healthcare and OphtAI Announce their Partnership in EMEA

Topcon Healthcare and OphtAI have partnered to integrate OphtAI's AI algorithm into Topcon's Harmony Referral System, providing eye care professionals with smarter access to AI services. This integration allows for early detection of eye pathologies like diabetic retinopathy, macular edema, glaucoma, and AMD.

2026-03

Taylor & Francis Online (Journal of Clinical Medicine)

Comparison of 21 artificial intelligence algorithms in automated diabetic retinopathy screening using handheld fundus camera

This study compared the performance of 21 AI algorithms, including OphtAI, for referable diabetic retinopathy screening using handheld fundus cameras in a real-world setting. The results showed a wide variation in agreement, sensitivity, and specificity among the algorithms.

2024-05

Videos

Product demos, reviews, and walkthroughs for OphtAI.

Demain La Tech avec OphtAI

demaintv

Arab Health 2020 - Ru00e9gion Hauts de France - Ophtai - Alexandre Le Guilcher

Mickael Genet

What are Eye Floaters? ufffc

Stay Curious, My Friends

June 6, 2024

Vijay Chauhan

ud83cudfac Clap de fin sur cette u00e9dition 2025 de #SANTEXPO !

Evolucare Technologies

Optomed Q3u201922: Kasvua haasteista huolimatta

inderesTV

View all on YouTube

Frequently Asked Questions

How does OphtAI integrate into my existing clinical workflow and EMR system?

OphtAI is designed for easy integration into your existing IT tools for patient care, often launching automatically without user intervention. It can be accessed via a web browser, a desktop application that detects photos in a PC directory, or an API for integration into partner software. While specific EMR integrations would need to be confirmed with OphtAI, AI-enabled EMR integration can support various tasks like documentation, referrals, treatment plan tracking, and analytics, ultimately streamlining workflows and reducing manual entry.

What are the regulatory approvals and compliance standards for OphtAI?

OphtAI is a Class IIa Medical Device, certified in the European Union (compliant with ISO 13485 and MDR 2017/745) and by Health Canada, with UKCA registration. It also anticipates compliance with the European AI Act. The solution adheres to GDPR for data protection and security, processing data in certified Health Data Hosting (HDS) environments, and does not store patient-related data for security and anonymization purposes.

How accurate and reliable is OphtAI in detecting ophthalmic conditions compared to human experts?

OphtAI has demonstrated high sensitivity and specificity in detecting retinal conditions, including diabetic retinopathy, glaucoma, and age-related macular degeneration (AMD), with performance comparable to or even outperforming expert human readers. Studies have shown its ability to standardize image interpretation, reduce inter-observer variability, and effectively prioritize at-risk patients. It provides consistent and detailed feedback, including predictive values and heat maps, to help users understand the results.

What are the main limitations of using OphtAI in a clinical setting?

While powerful, AI tools like OphtAI do not replace clinical judgment; they enhance it. Limitations can include the need for huge databases for training, significant computing power, and increased processing time for complex neural networks. Also, AI generally detects more overt pathologies with higher accuracy compared to subtle findings. OphtAI specifically processes standard fundus examination images and does not process corneal images or retinal images from fluorescein angiography or other markers.

What are the alternatives to OphtAI for AI-powered clinical decision support in ophthalmology?

Several other AI tools and platforms offer clinical decision support in ophthalmology. Examples include Eyenuk EyeArt and IDx-DR for diabetic retinopathy screening, Optovue iWellness for retinal diseases, and RetInSight solutions for AMD monitoring. Other general clinical decision support systems like UpToDate Expert AI, DynaMed, and OpenEvidence are also available, though they may not be ophthalmology-specific.

What is the pricing model for OphtAI, and how can it impact the cost-effectiveness of my practice?

While specific pricing details are not publicly available, OphtAI operates on a credit-based system where users can buy credits for analyses. Studies suggest that using AI for diabetic retinopathy screening, such as OphtAI DR, can reduce screening costs, with one study indicating a reduction of more than $15 USD per patient. This cost-effectiveness stems from its ability to automate initial image review, sort cases by urgency, and save medical staff significant time by reducing repetitive tasks.

What specific ophthalmic conditions can OphtAI detect and assist with in diagnosis?

OphtAI is capable of detecting and assisting with the diagnosis of major retinal diseases, including diabetic retinopathy (DR), diabetic macular edema (DME), glaucoma, and age-related macular degeneration (AMD), including age-related maculopathy (ARM). It can also provide a severity rating for DR and identify the location of detected lesions.